Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Delivery Systems | 17 | 2024 | 216 | 3.720 |
Why?
|
| Nanoparticles | 12 | 2024 | 273 | 2.970 |
Why?
|
| Nanostructures | 4 | 2020 | 62 | 2.360 |
Why?
|
| Polymers | 4 | 2018 | 114 | 1.720 |
Why?
|
| Drug Carriers | 4 | 2019 | 109 | 1.200 |
Why?
|
| Eye Diseases | 6 | 2018 | 31 | 1.130 |
Why?
|
| Zebrafish | 1 | 2024 | 95 | 0.870 |
Why?
|
| Ear, Inner | 2 | 2024 | 9 | 0.810 |
Why?
|
| Pharmaceutical Preparations | 2 | 2020 | 44 | 0.810 |
Why?
|
| Polyesters | 3 | 2017 | 33 | 0.790 |
Why?
|
| Molecular Targeted Therapy | 3 | 2019 | 123 | 0.780 |
Why?
|
| Polyethylene Glycols | 3 | 2017 | 93 | 0.740 |
Why?
|
| Trabecular Meshwork | 2 | 2019 | 16 | 0.740 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2019 | 74 | 0.720 |
Why?
|
| Neurodegenerative Diseases | 2 | 2019 | 21 | 0.690 |
Why?
|
| Peptides | 3 | 2018 | 280 | 0.680 |
Why?
|
| Proteins | 3 | 2018 | 244 | 0.680 |
Why?
|
| Labyrinth Diseases | 1 | 2019 | 3 | 0.650 |
Why?
|
| Muramidase | 2 | 2018 | 13 | 0.640 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2018 | 20 | 0.610 |
Why?
|
| Nanomedicine | 4 | 2019 | 62 | 0.600 |
Why?
|
| Cytoskeletal Proteins | 1 | 2017 | 42 | 0.570 |
Why?
|
| Dexamethasone | 1 | 2017 | 53 | 0.570 |
Why?
|
| Conjunctivitis, Allergic | 1 | 2017 | 1 | 0.570 |
Why?
|
| Posterior Eye Segment | 1 | 2016 | 2 | 0.560 |
Why?
|
| Dry Eye Syndromes | 1 | 2017 | 5 | 0.560 |
Why?
|
| Immunoglobulin G | 2 | 2018 | 266 | 0.560 |
Why?
|
| Ophthalmic Solutions | 1 | 2016 | 27 | 0.560 |
Why?
|
| Eye | 1 | 2016 | 35 | 0.550 |
Why?
|
| Glycoproteins | 1 | 2017 | 118 | 0.550 |
Why?
|
| Uveitis | 1 | 2017 | 23 | 0.540 |
Why?
|
| Intravitreal Injections | 1 | 2016 | 33 | 0.530 |
Why?
|
| Macromolecular Substances | 1 | 2016 | 52 | 0.510 |
Why?
|
| Eye Proteins | 1 | 2017 | 197 | 0.510 |
Why?
|
| Animals | 13 | 2024 | 9954 | 0.460 |
Why?
|
| Cell Survival | 3 | 2024 | 393 | 0.460 |
Why?
|
| Brain | 1 | 2019 | 697 | 0.440 |
Why?
|
| Gels | 4 | 2018 | 26 | 0.430 |
Why?
|
| Drug Compounding | 3 | 2018 | 29 | 0.420 |
Why?
|
| Humans | 20 | 2021 | 26856 | 0.420 |
Why?
|
| Cell Line | 5 | 2024 | 671 | 0.400 |
Why?
|
| Hydrogels | 2 | 2024 | 51 | 0.350 |
Why?
|
| Nanotechnology | 3 | 2021 | 67 | 0.350 |
Why?
|
| Delayed-Action Preparations | 4 | 2021 | 38 | 0.330 |
Why?
|
| RAW 264.7 Cells | 3 | 2018 | 21 | 0.320 |
Why?
|
| Extracellular Vesicles | 2 | 2019 | 29 | 0.320 |
Why?
|
| Mice | 5 | 2024 | 4402 | 0.310 |
Why?
|
| Drug Liberation | 2 | 2018 | 23 | 0.300 |
Why?
|
| Prodrugs | 3 | 2017 | 29 | 0.290 |
Why?
|
| Membrane Transport Proteins | 3 | 2016 | 65 | 0.290 |
Why?
|
| Administration, Ophthalmic | 4 | 2017 | 8 | 0.240 |
Why?
|
| Lignans | 1 | 2024 | 10 | 0.240 |
Why?
|
| Biphenyl Compounds | 1 | 2024 | 22 | 0.240 |
Why?
|
| Cisplatin | 1 | 2024 | 172 | 0.220 |
Why?
|
| Tissue Distribution | 2 | 2020 | 132 | 0.210 |
Why?
|
| Particle Size | 3 | 2017 | 96 | 0.200 |
Why?
|
| Polyphenols | 1 | 2021 | 17 | 0.180 |
Why?
|
| Chemistry, Pharmaceutical | 2 | 2018 | 26 | 0.180 |
Why?
|
| Microtechnology | 1 | 2020 | 4 | 0.180 |
Why?
|
| Bacterial Infections | 1 | 2021 | 56 | 0.180 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2019 | 14 | 0.170 |
Why?
|
| Technology, Pharmaceutical | 1 | 2019 | 9 | 0.160 |
Why?
|
| Aqueous Humor | 1 | 2019 | 24 | 0.160 |
Why?
|
| Regenerative Medicine | 1 | 2019 | 17 | 0.160 |
Why?
|
| Biotechnology | 1 | 2019 | 16 | 0.160 |
Why?
|
| Intraocular Pressure | 1 | 2019 | 61 | 0.160 |
Why?
|
| Prostaglandins A | 1 | 2017 | 1 | 0.150 |
Why?
|
| Surface Properties | 1 | 2017 | 132 | 0.140 |
Why?
|
| Temperature | 1 | 2018 | 207 | 0.140 |
Why?
|
| Patents as Topic | 1 | 2017 | 5 | 0.140 |
Why?
|
| Cell Transplantation | 1 | 2016 | 10 | 0.140 |
Why?
|
| Drug Discovery | 1 | 2017 | 32 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 496 | 0.140 |
Why?
|
| Antiviral Agents | 1 | 2017 | 104 | 0.130 |
Why?
|
| Drug Design | 1 | 2017 | 62 | 0.130 |
Why?
|
| Chromatography, Gel | 1 | 2016 | 36 | 0.130 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2016 | 35 | 0.130 |
Why?
|
| X-Ray Diffraction | 1 | 2016 | 41 | 0.130 |
Why?
|
| Dendrimers | 1 | 2016 | 15 | 0.130 |
Why?
|
| Hypertension | 1 | 2019 | 304 | 0.130 |
Why?
|
| Cytokines | 1 | 2018 | 437 | 0.130 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2016 | 176 | 0.120 |
Why?
|
| Ganciclovir | 1 | 2015 | 7 | 0.120 |
Why?
|
| Dipeptides | 1 | 2015 | 22 | 0.120 |
Why?
|
| Polyglycolic Acid | 1 | 2015 | 36 | 0.120 |
Why?
|
| Liposomes | 1 | 2016 | 142 | 0.120 |
Why?
|
| Hydrocortisone | 1 | 2015 | 88 | 0.120 |
Why?
|
| Cells, Cultured | 1 | 2017 | 969 | 0.120 |
Why?
|
| Lactic Acid | 1 | 2015 | 89 | 0.120 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2013 | 2 | 0.110 |
Why?
|
| Biological Availability | 3 | 2021 | 43 | 0.110 |
Why?
|
| Fluoroquinolones | 1 | 2013 | 16 | 0.110 |
Why?
|
| Retina | 1 | 2017 | 421 | 0.110 |
Why?
|
| Quality of Life | 1 | 2017 | 463 | 0.110 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2013 | 90 | 0.100 |
Why?
|
| Inflammation | 1 | 2017 | 598 | 0.100 |
Why?
|
| Neoplasms | 2 | 2019 | 756 | 0.090 |
Why?
|
| Emulsions | 2 | 2015 | 23 | 0.060 |
Why?
|
| Solubility | 1 | 2021 | 73 | 0.050 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2021 | 23 | 0.050 |
Why?
|
| Biological Products | 1 | 2021 | 60 | 0.040 |
Why?
|
| Cell Communication | 1 | 2019 | 66 | 0.040 |
Why?
|
| Blindness | 1 | 2019 | 34 | 0.040 |
Why?
|
| Glaucoma | 1 | 2019 | 52 | 0.040 |
Why?
|
| Tomography, Optical Coherence | 1 | 2019 | 89 | 0.040 |
Why?
|
| Exosomes | 1 | 2019 | 86 | 0.040 |
Why?
|
| Genetic Engineering | 1 | 2018 | 23 | 0.040 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 2017 | 1 | 0.040 |
Why?
|
| Micelles | 1 | 2017 | 19 | 0.040 |
Why?
|
| Diffusion | 1 | 2016 | 37 | 0.030 |
Why?
|
| Permeability | 1 | 2016 | 58 | 0.030 |
Why?
|
| Octreotide | 1 | 2016 | 4 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 731 | 0.030 |
Why?
|
| Biological Transport | 1 | 2016 | 109 | 0.030 |
Why?
|
| Chickens | 1 | 2016 | 59 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 200 | 0.030 |
Why?
|
| Catalase | 1 | 2016 | 48 | 0.030 |
Why?
|
| Corneal Keratocytes | 1 | 2015 | 1 | 0.030 |
Why?
|
| Ocular Absorption | 1 | 2015 | 1 | 0.030 |
Why?
|
| Polyvinyl Alcohol | 1 | 2015 | 3 | 0.030 |
Why?
|
| Poloxamer | 1 | 2015 | 3 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2015 | 28 | 0.030 |
Why?
|
| Chitosan | 1 | 2015 | 31 | 0.030 |
Why?
|
| Proteomics | 1 | 2016 | 177 | 0.030 |
Why?
|
| Microspheres | 1 | 2015 | 47 | 0.030 |
Why?
|
| Insulin | 1 | 2016 | 309 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 146 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2015 | 134 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 1474 | 0.030 |
Why?
|
| Half-Life | 1 | 2013 | 32 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 1394 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2013 | 261 | 0.030 |
Why?
|
| Kinetics | 1 | 2013 | 538 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 656 | 0.020 |
Why?
|